Noxopharm Ltd. (AU:NOX) has released an update.
Noxopharm Limited, an innovative biotech company, has revealed significant advancements in its Chroma™ technology platform, with promising results in brain cancer drug development and early successes in leukemia treatment. Their novel drug candidates have shown a remarkable ability to halt tumor growth in glioblastoma by over 75% and possess the rare ability to cross the blood-brain barrier. Additionally, they’ve pinpointed a new drug that addresses drug resistance in Acute Myeloid Leukaemia, marking a potential breakthrough in the treatment of these challenging cancers.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.
